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DNA double-strand breaks (DSBs) represent a
serious threat for hematopoietic stem cells (HSCs).
How cytokines and environmental signals integrate
the DNA damage response and contribute to HSC-
intrinsic DNA repair processes remains unknown.
Thrombopoietin (TPO) and its receptor, Mpl, are
critical factors supporting HSC self-renewal and
expansion. Here, we uncover an unknown function
for TPO-Mpl in the regulation of DNA damage
response. We show that DNA repair following
g-irradiation (g-IR) or the action of topoisomerase-II
inhibitors is defective in Mpl/ and in wild-type
mouse or human hematopoietic stem and progenitor
cells treated in the absence of TPO. TPO stimulates
DNA repair in vitro and in vivo by increasing
DNA-PK-dependent nonhomologous end-joining
efficiency. This ensures HSC chromosomal integrity
and limits their long-term injury in response to
IR. This shows that niche factors can modulate
the HSC DSB repair machinery and opens new
avenues for administration of TPO agonists for
minimizing radiotherapy-induced HSC injury and
mutagenesis.
INTRODUCTION
Double-strand breaks (DSBs) in genomic DNA are generated
endogenously during replication or through exogenous treat-
ments with genotoxic agents such as ionizing radiations. In
mammalian cells, DSBs are removed by two main repair path-
ways: homologous recombination (HR) and nonhomologous
end-joining (NHEJ). NHEJ is regarded as the predominant mech-
anism for DSB repair in vertebrates and in response to irradiation(IR) (Iliakis et al., 2004). Central to NHEJ are the DNA-PK
complex, composed of the DNA-PK catalytic subunit and the
Ku80/Ku70 heterodimer, and the DNA Ligase IV/XRCC4/XLF
complex. NHEJ is considered intrinsically error prone. However,
although it frequently causes small alterations in DNA sequence
around the break site, the classical NHEJ usually does not join
unlinked DNA ends. In the absence of key canonical NHEJ
components, a backup DNA-PK-independent version of NHEJ
accounts for residual end-joining of DSBs and results in major
genomic rearrangements, including chromosomal deletions
and translocations like those at the origin of leukemia (Ferguson
et al., 2000; Guirouilh-Barbat et al., 2004; Iliakis et al., 2004;
Weinstock et al., 2007).
Bone marrow (BM) injury is one of the major limiting factors for
cancer therapies that use DNA-damaging agents, such as IR and
chemotherapeutic drugs. Besides acute myelosuppression,
resulting from apoptosis of proliferating hematopoetic progen-
itor cells (HPCs) and reversible for nonlethal doses, IR induces
residual BM injury due to loss of hematopoietic stem cell (HSC)
reserves or functions (Shao et al., 2010; Simonnet et al., 2009;
Wang et al., 2006). Moreover, DNA-damaging agent-induced
risk of cancer is very high for the hematopoietic tissue. Indeed,
secondary acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS) are concerning complications of these thera-
pies. Because they maintain hematopoiesis throughout their
life span, HSCs have an increased risk of accumulating genomic
anomalies. Maintenance of genomic integrity is also crucial for
preservation of HSC self-renewal (Ito et al., 2004; Nijnik et al.,
2007; Rossi et al., 2007). Therefore, approaches for improving
the safety of anticancer DNA agents require careful analysis of
HSC response to DNA damage. Limited data are available on
the mechanisms involved in DNA repair in HSCs. Recent data
demonstrated that DSB repair through NHEJ is necessary for
HSC maintenance, given that mice deficient for DNA Ligase IV
or KU80 display age-progressive loss of HSC functions (Nijnik
et al., 2007; Rossi et al., 2007). However, the obligatory use of
NHEJ to repair IR-induced DNA damage in quiescent HSCs
has been shown to promote high levels of mutagenesis (MohrinCell Stem Cell 12, 37–48, January 3, 2013 ª2013 Elsevier Inc. 37
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Figure 1. Mpl Loss Confers g-IR Sensitivity
and Impairs DNA Repair
(A) Survival Kaplan-Meier curves of 8-week-old
WT and Mpl/ mice exposed to 8 and 9 Gy TBI
(n = 3).
(B) In vitro LSK clonogenic assay. Means ± SEM of
7 day colonies after IR normalized to nontreated
sample numbers are shown (n = 3).
(C and D) gH2AX foci expression inWT andMpl/
HSPCs 24 hr following 2 Gy TBI or not (NIR). (C)
Percentage of LSK cells displaying more than
three gH2AX foci. Means + SEM, n = 5 (NIR), n = 4
(IR). (D) gH2AX-positive LSK-CD34 cells de-
tected by flow cytometry. Means + SEM (n = 3) and
representive histograms are shown.
(E and F) gH2AX-positive cells (E) and foci-number
repartition (F) inMpl/,Mpl/+, and WT LSK cells
irradiated (2 Gy) in vitro and cultured in complete
medium for the indicated times. Means + SEM
from three independent experiments on pools of
three to five mice are shown. See also Figure S1.
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TPO Regulates DNA Repair in HSCset al., 2010). HSCs are also regulated through interactions with
the niche environment and growth factors controlling the
balance between quiescence, proliferation, and differentiation.
How these signals contribute to the HSC-intrinsic DNA repair
process is currently unknown.
Thrombopoietin (TPO) and its receptor Mpl are master regu-
lators of both megakaryopoiesis and HSCs. TPO has been
shown to increase HSC interaction with the osteoblastic niche
and to support HSC quiescence and expansion posttransplan-
tation (Fox et al., 2002; Qian et al., 2007; Yoshihara et al.,
2007). Mice deficient for TPO or Mpl display increased HSC
cycling and age-progressive loss (Qian et al., 2007; Yoshihara
et al., 2007). Inactivating mutations of the Mpl receptor in
humans cause thrombocytopenia and BM failure in early
childhood, a syndrome called congenital amegakaryocytic
thrombocytopenia (CAMT) (Maserati et al., 2008), whereas
mutations resulting in its constitutive activation are involved in
myeloproliferative disorders (Pardanani et al., 2006). We show
here that Mpl-deficient mice and HSPCs display increased
radiosensitivity due to a defective repair function. We uncover
a specific function of TPO in the regulation of HSC DNA
damage response. TPO acts by increasing DNA-PK-dependent
NHEJ repair efficiency. This shows that HSC environmental
factors can control the DSB repair machinery to ensure chro-
mosomal integrity and limit their long-term residual injury in
response to IR.38 Cell Stem Cell 12, 37–48, January 3, 2013 ª2013 Elsevier Inc.RESULTS
Increased IR Sensitivity and
Impaired DNA Repair in Mpl–/–
HSPCs
Previous studies have reported the
difficulty of transplanting Mpl/ mice
(Wicke et al., 2010). To analyze this
further, we subjected wild-type (WT) and
Mpl/ mice to various doses of total-
body IR (TBI). The doses of 9 and 8 Gy
were clearly sublethal for WT mice,whereas they induced rapid death of allMpl/mice (Figure 1A).
Clonogenic assays showed thatMpl/ LinSca+Kit+ cells (here-
after referred to as HSPCs or LSK cells) were less resistant than
WT LSK cells to low doses of IR, indicating a radiosensitive
phenotype (Figure 1B). The dose of 2 Gy was chosen for further
examination of this phenotype.
We then asked whether the lower radioresistance of Mpl/
HSPCs could be due to DNA repair defects. Thus, we first
examined the presence of gH2AX nuclear foci, a commonly
used surrogate marker of DSB formation. A slightly higher
proportion of Mpl/ LSK cells expressed spontaneous gH2AX
foci compared to WT cells, although this remained low.
Twenty-four hours after TBI, a significantly greater number of
WT LSK cells harbored gH2AX foci, and this number was further
increased inMpl/mice (Figure 1C). The number of gH2AX foci
detected by flow cytometry was also increased in Mpl/ HSC-
enriched LSK-CD34 cells (Figure 1D).
Second, we assessed DNA repair by analyzing gH2AX foci
disappearance kinetics. Thus, LSK cells were irradiated in vitro
and analyzed at various times of culture in a medium containing
a cocktail of cytokines including TPO (complete medium).
Maximum gH2AX foci formation was observed immediately
after IR, and it was not significantly different between WT and
Mpl/ cells. WT LSK cells had already started resolving their
foci at 5 hr post-IR, and 62 ± 3% of cells harboring foci had
disappeared at 24 hr. By contrast, at that time, the majority of
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Figure 2. TPO Specifally Increases DNA
Repair in Mouse and Human HSPCs In Vitro
(A–C) gH2AX staining in LSK cells (A and B) and
LSK-CD34 cells (C) treated with 2 Gy IR (A and C)
or 100 mMetoposide (Eto) for 30min (B) in vitro and
cultured for the indicated times in complete
medium or without TPO or SCF. Means + SEM of
nine (A) or three (B and C) independent experi-
ments on pools of three to five mice are shown.
(D) Comet tail moment and representative pictures
of Lin cells treated as in (A). Means + SEMof three
independent experiments (nine mice per group).
(E) gH2AX foci in human CD34+C38 cells after IR
(2 Gy) and culture in complete medium or without
TPO. Left: Cells expressing more than four gH2AX
foci 5 hr post-IR. Results are expressed as a
percentage of positive cells in complete medium.
Means + SEM, n = 3. Right: Foci-number reparti-
tion 5 and 24 hr after IR. A representative experi-
ment is shown. See also Figure S2.
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TPO Regulates DNA Repair in HSCsMpl/ cells still stained positively for gH2AX, and the majority of
them contained four or more foci (Figures 1E and 1F), indicative
of prolonged DNA damage in Mpl/ HSPCs. Interestingly,
a similar defect was observed in Mpl+/ cells (Figure 1E), indi-
cating that the level of Mpl expression is critical for correct
DNA repair in response to IR.
To analyze whether this persistent DNA damage resulted from
defective DSB repair, we performed single-cell comet assays in
neutral conditions that measure DSBs specifically. Just after IR,
all the cells displayed comparable amounts of DNA breaks.
However, whereas WT cells rejoined 2/3 of the breaks in 2 hr,
the great majority of them remained unrepaired in Mpl/ cells
(Figure S1A available online). In addition, when the extent of
damage was quantified on a 0 (undamaged) to 3 (very damaged)
scale according to the tail length, it appeared that the severity of
IR-induced DNA damage was greatly enhanced in Mpl/
(Figure S1B).
TPO-Mpl Signaling Specifically Regulates DSB Repair
in HSCs
To exclude the possibility that the constitutive lack of Mpl leads
to increased DNA damage due to chronic changes, we analyzed
the effect of acute TPO signaling upon IR. Thus, we switched the
cells from the complete medium to the same medium containing
all cytokines but TPO. The presence of TPO did not affect the
maximum levels of gH2AX foci or break formation, showingCell Stem Cell 12, 37–that TPO did not prevent DNA damage.
However, LSK cells irradiated and
cultured in TPO-freemediumwere greatly
impaired in their capacity to resolve
gH2AX foci (Figure 2A). Similar results
were found by using etoposide and doxo-
rubicin (DXR) for inducing DSBs (Figures
2B and S2A). DNA comet tail repair was
also greatly altered in the absence of
TPO (Figure 2D). The defects were similar
in their extent to those observed withMpl/ cells. Removal of TPO to Mpl/ LSK cell cultures had
no effect (Figure S2B), showing that TPO acts through Mpl
only. In agreement with the higher Mpl expression in HSCs
than in progenitors (Qian et al., 2007), TPO had an even more
striking effect in improving DNA damage resolution in LSK-
CD34 cells (Figure 2C). This indicates that the DNA repair
defect of Mpl/ cells results from a specific loss of TPO
signaling. TPO also increased gH2AX foci disappearance in
CD34+CD38 human HSPCs (Figures 2E and S2C) and in
a human cell line expressing Mpl, UT7-Mpl (Figure S2D), which
can be grown in erythropoietin (EPO) or TPO (Hamelin et al.,
2006). Kinetics analysis indicated that the protective effect of
TPO required the presence of TPO shortly before IR and was
abolished when TPO was added to the medium after IR (data
not shown).
TPO could also favor DNA repair in vivo. Indeed, TPO injection
to WT but not to Mpl/ mice just before TBI or DXR treatment
(Figure 3A) significantly reduced the number of LSK cells
displaying gH2AX foci at 5 or 16 hr compared to mice treated
with PBS (Figures 3B and 3C). The TPO agonist Romiplostim
(Le´on et al., 2012) induced a similar effect (Figure 3B). As
observed in vitro, an even more striking effect of TPO was
observed in HSC-enriched LSK-CD34 cells (Figure 3D).
In contrast with TPO, removal of stem cell factor (SCF; Fig-
ures 2A, 2D, and S2B) or Flt3 ligand (Flt3-L; data not shown)
did not impair the kinetics of IR-induced gH2AX foci or DSB48, January 3, 2013 ª2013 Elsevier Inc. 39
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Figure 3. TPO Specifically Increases the
DNA Repair In Vivo
(A) Experimental design for in vivo cytokines and
DNA-damaging agent treatments. TPO (8 mg/kg),
Romiplostim (100 mg/kg), SCF, or Flt3-L (50 mg/kg)
were injected 30 min before TBI (2 Gy) or DXR
(4 mg/kg).
(B and C) gH2AX staining in LSK cells isolated 5 hr
after TBI (B) or 16 hr after DXR treatment (C).
Results are normalized to the means of gH2AX-
positive cells from PBS-injected animals. Means +
SEM (B, n = 5; C, n = 4).
(D) Means + SEM of gH2AX-positive LSK-CD34
cells 16 hr after treament with the indicated cyto-
kines and TBI. Each dot represents an individual
mouse.
(E) gH2AX staining in LSK cells treated 24 hr
before with TPO (800 mg/kg) or Kit (2 mg/kg)
neutralizing antibodies and TBI (n = 5). Results are
expressed as in (B).
(F and G) Cell-cycle distribution measured by
Hoescht and Pyronin Y staining in LSK (F) or LSK-
CD34 (G) cells from mice treated as in (B).
Means + SEM (n = 3) and representative flow-
cytometry profiles are shown. ns, not significant.
See also Figure S3.
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TPO Regulates DNA Repair in HSCsdisappearance in WT or Mpl/ LSK cells. Likewise, injection of
SCF or Flt3-L (He´rodin et al., 2003) to mice before TBI did not
reduce gH2AX foci accumulation in LSK-CD34 cells (Figure 3D).
Injection of TPO-neutralizing antibodies significantly increased
TBI-induced gH2AX foci accumulation, whereas the c-Kit
neutralizing antibody ACK2 (Xue et al., 2010) had no effect (Fig-
ure 3E). This indicates that TPO has a unique effect onHSCDNA-
damage responses in vivo and in vitro. Confirming these results,
HSPCs from KitW-v/W-v mutant mice did not display increased
DNA damage upon TBI (Figure S2E).
In addition to defects in DNA repair, decreased DNA damage
and radiosensitivity can result from altered apoptotic or cell-
cycle responses. Thus, we next tested whether TPO signaling
could also modulate these cellular outcomes after IR. WT and
Mpl/ LSK cells showed similar degrees of caspase 3 and cas-
pase 7 activation at 24 hr post-IR (2 Gy) in vitro (Figure S3A).
Likewise, a low and similar percentage of WT and Mpl/ LSK
cells isolated 5 hr (data not shown) or 24 hr (Figure S3B) after
2 Gy TBI stained positive for annexin V. Thus, the Mpl/
HSPC radiosensitivity is not due to increased IR-induced early
apoptosis. Confirming these results, TPO had no effect on
apoptosis of WT LSK cells 24 hr after IR in vitro (Figure S3C).
Accordingly, induction of p53-dependent apoptotic genes40 Cell Stem Cell 12, 37–48, January 3, 2013 ª2013 Elsevier Inc.involved in IR-induced HSPC death
(Shao et al., 2010) was similar in the pres-
ence or the absence of TPO (Figure S3D).
At 5 hr after TBI, the proportions of
LSK and LSK-CD34 cells recovered
from the BM of PBS- or TPO-treated
mice were not significantly different
(data not shown). Cell-cycle analysis
using Hoechst and Pyronin Y staining
confirmed previous data showing thatthe LSK-CD34 HSC population contains a majority of G0
quiescent cells and fewer proliferative cells than the LSK cell
population (Figures 3F and 3G). Although TBI increased the
number of LSK cells in S-G2/M, it has no significant effect on
the total number of quiescent LSK and LSK-CD34 cells. Impor-
tantly, TPO treatment pre-TBI did not alter the cell-cycle status of
either LSK or LSK-CD34 cells compared to PBS treatment, at
a time when it already reduced gH2AX foci. Similar results
were observed at 16 hr post-TBI (Figure S3E). Moreover, expres-
sion of the cell-cycle regulators p57kip2 and p27Kip1, involved in
HSC quiescence (Qian et al., 2007; Yoshihara et al., 2007), re-
mained unchanged after TPO injection and TBI (Figure S3F).
Likewise, although the proportion of quiescent LSK cells
decreased significantly after 24 hr culture in vitro, the presence
of TPO in the medium had no effect on this phenomenon (Fig-
ure S3G). For determining whether TPO could give more time
to the cells to repair damaged DNA by slightly slowing down
the cell cycle, cell-division history of LSK cells irradiated
in vitro was also assessed using CFSE dilution assays. No differ-
ence was observed in cultures containing TPO or not, even at
early time points (Figure S3H). Finally, we could not detect
senescence by SA-b-galactosidase staining in WT or Mpl/
LSK cells (data not shown).
A B
C D
E F
G H
H
2A
X-
po
si
tiv
e 
ce
lls
H
2A
X-
po
si
tiv
e 
ce
lls
H
2A
X-
po
si
tiv
e 
ce
lls
Time after IR in vitro
Time after IR in vitro
Time after IR in vitro
0 hr 4 hr 8 hr 16 hr
0 hr 5 hr 24 hr
Figure 4. TPO Regulates a DNA-PK-Depen-
dent Pathway
(A and B) Percentages of gH2AX-positive cells in
LSK (A) or in LSK-CD34 (B) cells cultured in the
presence or absence of 10 mM NU7441 and
irradiated (2 Gy) in vitro. Means + SEM of three
separate experiments with four to six mice are
shown.
(C) Comet assays in Lin cells from mice as in (A)
and (B). Representative experiment out of three
similar experiments performed with cells pooled
from three to four mice is shown.
(D) Percentage of gH2AX-positive LSK cells from
SCID mice treated with PBS or TPO and TBI 16 hr
before. Means + SEM, n = 4.
(E–H) pSer2056-DNA-PK foci in UT7-Mpl (E and F)
or human CD34+ (G) and CD34+CD38 (H) HSPCs
cultured in medium containing TPO or not and IR
(2 Gy). (E and G) Means + SEM of the percentage
of cells with more than six foci from three inde-
pendent experiments. (F and H) Foci-number
repartition per cell 30 min after IR. Representative
experiments out of three performed. See also
Figure S4.
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TPO Regulates DNA Repair in HSCsThus, TPO-mediated decrease in DNA damage in HSPCs and
HSCs is unrelated to their cell-cycle status and is not due to
changes in quiescence, proliferation, or apoptosis in vivo and
in vitro. Rather, this effect seems to result specifically from an
alteration in the DNA repair process.
TPO Regulates a DNA-PK-Dependent NHEJ Pathway
We next examined the mechanism involved in TPO-mediated
DSB repair. HR and NHEJ are the two major DSB repairCell Stem Cell 12, 37–pathways. The above data show that
TPO regulates DNA damage in HSC-
enriched, mostly quiescent LSK-CD34
cells (65%–80% G0), HSPCs (LSK cells,
30%–40% G0), proliferating Lin progen-
itors and UT7-Mpl cells. This suggests
that the mechanism involved is different
from HR which acts only during the G2
and S phases. Supporting this hypoth-
esis, TPO did not increase IR-induced
Rad51 foci formation, an in vivo functional
marker of HR (Figure S4A), and it could
not improve repair of DSBs induced by
replicative stresses such as camptotecin
and hydroxyurea (data not shown).
NHEJ is the predominant repair mecha-
nism for DSBs resulting from IR (Iliakis
et al., 2004). Thus, we then tested this
pathway by analyzing the involvement of
its main enzyme, DNA-PK. Addition of
the specific DNA-PK inhibitor NU7441 to
TPO-containing cultures of both LSK
and LSK-CD34 cells abolished TPO-
improved gH2AX foci resolution to the
level observed in the absence of TPO
(Figures 4A and 4B). Similarly, NU7441inhibited the fast rejoining of DSBs induced by TPO, as
measured by neutral comet assays (Figure 4C). Interestingly, in
the absence of TPO a slow repair process occurred on which
NU7441 had no effect, showing that this repair process takes
place in a DNA-PK-independent manner. Confirming the impor-
tance of DNA-PK activation in TPO-mediated DNA repair, TPO
injection to severe combined immunodeficiency (SCID) mice,
which are NHEJ repair deficient as a result of a DNA-PKcs
mutation, did not decrease TBI-induced LSK gH2AX foci48, January 3, 2013 ª2013 Elsevier Inc. 41
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Figure 5. TPO Increases NHEJ Repair Effi-
ciency
(A) Quantification of NHEJ activity in WT, Mpl/,
or Mpl+/ LinKit+ cells, expressed as the ratio of
double-positive GFP+DsRed+ cells to total DsRed
cells (n = 8).
(B) The NHEJ substrate stably incorporated in
UT7-Mpl cells.
(C and D) Frequencies of inversion (C, CD8+) or
deletion (D, CD4+) events in the presence or
absence of TPO or NU7441, 72 hr after I-SceI
electroporation. A representative experiment
showing means + SEM of events obtained from
three independent clones.
(E) Representative experiment of I-SceI expres-
sion 72 hr after electroporation in EPO or TPO.
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TPO Regulates DNA Repair in HSCsformation (Figure 4D). IR has been shown to induce phosphory-
lation of DNA-PK at Ser2056 and Thr2609, and pDNA-PK foci
formation can be used as an in vivo functional marker of NHEJ
activity (Chan et al., 2002; Chen et al., 2005). To test whether
TPO could affect DNA-PK activation, we used human cells,
because the available pDNA-PK antibodies could not detect
DNA-PK in mouse cells. According to previous studies (Chen
et al., 2005), pDNA-PK is rapidly induced upon IR and accu-
mulates in nuclear foci (Figure S4B). In UT7-Mpl as well as in
CD34+ and CD34+C38 human primary HSPCs, the presence
of TPO led to a significant increase in IR-induced pSer2056-
and pThr2609-DNA-PK foci formation (Figures 4E–4H and
S4C). By contrast, total DNA-PK gave a diffuse signal that did
not change upon IR or TPO treatment (Figure S4B).
To confirm the activation of NHEJ repair by TPO, we examined
NHEJ activity. First, we transfected WT and Mpl-deficient
LinKit+ cells with a plasmid-based episomal DSB end-rejoining
assay, in which the religation leads to green fluorescent protein
(GFP) expression (Seluanov et al., 2004). This assay showed
that NHEJ activity in response to IR was significantly decreased
inMpl/ andMpl+/ progenitors (Figure 5A). Second, to assess42 Cell Stem Cell 12, 37–48, January 3, 2013 ª2013 Elsevier Inc.NHEJ activity more thoroughly, we used
an intrachromosomal substrate (Figure
5B) stably introduced in UT7-Mpl cells
and introduced DSBs using the meganu-
clease HA-I-SceI (Guirouilh-Barbat et al.,
2004). NHEJ events scored by CD4 or
CD8 expression were greatly enhanced
in cells treated with TPO (Figures 5C
and 5D), whereas I-SceI expression was
similar in both conditions (Figure 5E). As
a control, NU7441 completely abrogated
NHEJ activity. Taken together, these
results show that TPO stimulates DNA-
PK activity and NHEJ-mediated DNA
repair.
TPO Confers Genomic Stability in
Response to DNA Damage
Defects in DNA-PK-dependent NHEJ
repair lead to a dramatic increase in large
deletions and translocations (Fergusonet al., 2000; Weinstock et al., 2007). This suggests that the loss
of TPO signal may lead to enhanced generation of misrepaired
HSPCs. Indeed, cells derived from IR-exposedMpl/ LSK cells
showed significantly higher chromosomal aberrations than WT
controls (Figure 6A). Spectral karyotyping analysis using fluores-
cence in situ hybridization (FISH) probes specific for chromo-
somes 2, 6, and 12 showed that BM cells isolated from Mpl/
mice 24 hr post-TBI displayed three times more chromosomal
translocations than those from WT mice (Figure 6B). No signifi-
cant difference was found between WT and Mpl/ mice in the
absence of IR (Figures 6B and 6C).
Lin progenitors isolated from WT mice 5 months post-TBI
showed increased genomic instability compared to their nonirra-
diated age-matched counterparts, and this was further accentu-
ated in cells from Mpl/ mice (Figure 6C). This confirms the
increased genomic instability in Mpl/ cells and shows that
a greater number of Mpl/ cells expressing more aberrations
could persist for several months in vivo.
As Mpl/, WT HSPCs irradiated in vitro and cultured in the
absence of TPO harbored high numbers of chromosomal rear-
rangements (Figure 6A), showing that TPO-increased NHEJ
AB
C
Figure 6. Increased Genomic Instability in Mpl–/– HSPCs in
Response to DNA Damage
(A) Chromosomal aberrations in metaphases prepared from WT and Mpl/
LSK cells exposed to IR (2 Gy) in vitro and cultured in complete medium or
without TPO for 48 hr. Top: Means + SEM of aberrations per cell from three
independent experiments with three WT orMpl/mice. At least 50 complete
Cell Stem Cell
TPO Regulates DNA Repair in HSCscould prevent IR-mediated genomic instability in HSPC descen-
dants. We next examined whether TPO-induced DSB repair at
early times after IR could lead to long-term protection in vivo.
Thus, WT CD45.1 LSK cells cultured in the presence or absence
of TPO for short times before and after exposition to IR in vitro
(Figure S5A) were injected into lethally irradiated congenic
CD45.2 mice. Metaphase analysis of donor progenitor progeny
4 months posttransplantation showed that exposure to TPO
led to decreased genomic aberrations (Figure S5B).
To determine whether TPO could improve long-term adverse
effects of IR in vivo, mice were treated with TPO or PBS prior
to TBI and analyzed 3 months later (Figure 7A, stage 1). It has
been reported that despite seeming recovery of phenotypically
defined HSC number and cell cycle, DNA damage may persist
and HSC function remains altered several months after IR
(Marusyk et al., 2009; Simonnet et al., 2009). Accordingly, both
LSK and LSK-CD34 cells isolated from TBI mice harbored
more gH2AX foci than cells from nontreated mice (Figures 7B
and 7C), whereas their frequencies and proliferation and
quiescence statuses at that time were not significantly different
(Figures S5D–S5G). Injection of TPO or Romiplostim almost
completely abolished persistent DNA damage in HSCs and
HSPCs but had no effect on their number and cycle. In addition,
the in vitro LSK clonogenic potential was similar among the
three groups of mice (data not shown). Thus, TPO did not reduce
the numbers of gH2AX-positive LSK cells by inhibiting senes-
cence (Wang et al., 2006) or inducing proliferation. Three months
after TBI, metaphases from progenitor cells isolated from TPO-
injected mice also displayed greatly reduced chromosomal
aberrations (Figure 7D). This shows that TPO injection before
TBI limits IR-induced long-lasting DNA damage and genomic
instability in HSC/HSPCs.
Previous studies have shown that sublethal IR induces intense
HSC cycling to reconstitute hematopoiesis following acute
ablation of differentiated leukocytes (Ban and Kai, 2009; Maru-
syk et al., 2009; Michalak et al., 2010). Because designation
of HSCs requires contribution to hematopoiesis for at least
3months, the results above suggest that the progenitors isolated
5 months (Figure 6C) or 12 weeks (Figure 7D) after IR may repre-
sent HSC progeny and that TPO might restrain genomic insta-
bility in these cells. However, to distinguish this hypothesis
from a bystander effect (Lorimore et al., 2005) and determine
whether the reduced DNA damage in cells from TPO-treated
mice represents HSCs capable of long-term hematopoietic
reconstitution, LSK cells from stage 1 (Figure 7A) were used to
reconstitute lethally irradiated CD45.2 recipients. Four months
after reconstitution (Figure 7A, stage 2), the progenitor progeny
of LSK cells from the group that had received TBI and PBS dis-
played significantly increased levels of genomic rearrangements
compared to their nonirradiated counterparts or those treatedmetaphases were scored. Bottom: representative images with aberrations
indicated by arrows.
(B) Summary table and representative pictures of chromosomal translocations
measured by three-color FISH in WT and Mpl/ BM cell metaphases 24 hr
after TBI.
(C) Chromosomal aberrations analyzed as in (A) in WT and Mpl/ Lin
progenitors 5 months after TBI or in NIR age-matched controls. Each point
represents an individual mouse. Means ± SEM.
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Figure 7. TPO Confers Long-Term Protection and Genomic Stability to HSCs in Response to IR
(A) Experimental design to test TPO and TBI effects on genomic instability and long-term reconstitution in vivo.
(B and C) Frequencies of gH2AX-positive LSK (B) and LSK-CD34 (C) cells at stage 1 frommice that received PBS, TPO, or Romiplostim (Romi) before TBI. Each
dot represents an individual mouse. Means ± SEM are shown with the values above the dots indicating mean numbers.
(D) Frequencies of chromosomal aberrations in stage 1-Lin progenitors, detected by DAPI staining (n = 3 mice for each group).
(E–G) Analysis at stage 2. (E) Frequencies of chromosomal aberrations in CD45.1+Lin progenitor metaphases measured as in (D). Means + SEM of three
independent pools containing three mice per group are shown. (F and G) CD45.1 chimerism in peripheral blood (F) and in BM LSK cells 4 months post-
transplantation (G). Means ± SEM are shown (n = 7–9 mice per group). See also Figure S5.
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TPO Regulates DNA Repair in HSCswith TPO before TBI (Figure 7E). These results support previous
data showing that IR induces genomic instability in HSCs that
can be transmitted to their progeny (Mohrin et al., 2010). They
also indicate that TPO injection before TBI significantly reduced
this effect.
Increased DNA damage is linked to HSC dysfunction (Nijnik
et al., 2007; Rossi et al., 2007). We therefore assessed whether
TPO could also improve the reconstitution capacity of irradiated
cells. Supporting this possibility, the long-term engraftment of
LSK cells exposed to TPO before and after IR in vitro was
enhanced by almost 2-fold as compared to cells not treated
with TPO (Figure S5C). Competitive transplant experiments44 Cell Stem Cell 12, 37–48, January 3, 2013 ª2013 Elsevier Inc.(Figure 7A, stage 2) showed that LSK cells isolated from mice
that had received PBS and TBI 3 months before were far less
efficient than those from nonexposed mice in outcompeting
recipient cells, with a mean 9-fold decrease in the level of donor
contribution to peripheral blood leukocytes 4 months after
transplantation (Figure 7F). TPO injection partially restored this
defect with a 3- to 5-fold increase in donor CD45.1 chimerism
in the peripheral blood and in BM LSK cells (Figures 7F and
7G), although this level remained decreased compared to results
in mice reconstituted with LSK cells from nonirradiated donors.
No difference was found between the TPO and PBS groups at
6 weeks posttransplantation (Figure 7E), suggesting that TPO
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TPO Regulates DNA Repair in HSCstreatment improved HSC function of irradiated cells rather than
their short-term proliferation.
Altogether, these results show that the presence of TPO
in vitro or its injection in vivo just before IR reduced IR-induced
HSPC mutagenesis and loss function.
DISCUSSION
Management of acute myelosuppression following radiotherapy
has been significantly improved in recent years by the use of
growth factors. TPO injection shortly after IR has been shown
to accelerate progenitor recovery and prevent short-term pancy-
topenia (He´rodin et al., 2003; Neelis et al., 1998; Shibuya et al.,
1998) by inhibiting acute p53-dependent apoptosis (Pestina
et al., 2001). However, how TPO affects the HSC response to
DNA-damaging agents has never been studied. In addition,
protection from immediate IR-induced ablation does not always
correlate with maintenance of long-term proliferative capacities
(Marusyk et al., 2009). Much remains to be elucidated regarding
how cytokines and environmental signals integrate the DNA
damage responses in HSCs and regulate their long-term defects
following radiotherapy. In this study we uncover a specific func-
tion for TPO-Mpl in the regulation of DNA-PK-dependent NHEJ
activity that ensures efficient DNA repair and chromosomal
integrity of HSPCs and limits their residual injury in response to
IR or topoisomerase-II inhibitors. This is the first demonstration
that a cytokine involved in HSCs’ maintenancemay also regulate
their response to external DNA-damaging insults by controlling
the DSB repair machinery. A single injection of TPO prior to
TBI was sufficient to significantly improve DNA damage repair,
suggesting that endogenous HSCs in the BM niche respond
more similarly to DSB inducers and TPO signaling than isolated
HSCs ex vivo.
Recent data have shown that NHEJ activity is higher in quies-
cent HSCs than in proliferating HPCs (Mohrin et al., 2010).
Although our results do not call this into question, increased
HR does not seem to be the mechanism by which TPO favors
DSB repair. Indeed, TPO increases DSB repair similarly in
myeloid progenitors (LinKit+), mouse and human HSPC- and
HSC-enriched cell populations, and UT7-Mpl cells containing
various proportions of quiescent cells, without modifying their
cell cycle upon IR in vivo and in vitro. Moreover, we could not
observe a difference in Rad51 foci formation in LSK cells treated
with TPO or not, or inMpl/ cells (data not shown). Rather, our
results indicate that TPO increases DNA repair in these different
cell types by modulating the efficiency of the NHEJ pathway.
This is shown by (1) the complete inhibition of TPO-promoted
gH2AX resolution and DSB rejoining in both LSK and LSK-
CD34 cells by a specific inhibitor of DNA-PK; (2) the loss of
the TPO effect in vivo in DNA-PKcs-deficient SCID mice; (3)
the increased NHEJ efficiency in irradiated myeloid progenitors
and in UT7-Mpl upon TPO treatment; and (4) the increased
IR-induced DNA-PK phosphorylation at Ser2056 and Thr2609
in the presence of TPO. A Ser to Ala mutation at both sites has
been shown to compromise both radiation resistance and
NHEJ (Chan et al., 2002; Chen et al., 2005), suggesting that
TPO may be required for full DNA-PK activity. Additional studies
are required for determining how TPO signaling increases
DNA-PK phosphorylation. However, whatever the mechanism,the TPO effect on DNA-PK translates into a major effect on
NHEJ activity, as shown by the extent of decrease in NHEJ
efficiency in the absence of TPO. This fits with reports showing
that a partial defect in DNA-PK expression or phosphorylation
may be sufficient to underlie DSB repair defects and radiosensi-
tive phenotypes (Burma et al., 2006; Chan et al., 2002; Chen
et al., 2005).
In contrast to HR, NHEJ is intrinsically error prone. However, if
chromosomal integrity is the endpoint, it can be considered
as a conservative error-free process accommodating non-fully
complementary ends at the cost of limited mutagenesis. Indeed,
in the absence of major classic NHEJ actors, cells use a slower
backup DNA-PK-independent NHEJ pathway that has been
shown to be the primary mediator of IR-induced genome rear-
rangements (Iliakis et al., 2004; Martı´n et al., 2005). The genomic
instability and the significant increase in chromosomal transloca-
tions observed in the in vivo Mpl/ HSPC progeny or in cells
irradiated in the absence of TPO suggest that TPO-Mpl signaling
may favor DSB shunting in rapid classic DNA-PK-dependent
NHEJ repair. In agreement with this possibility, neutral comet
assays show that the DSB repair occurring in the absence of
TPO is slow, with 20%–30% of breaks still unrepaired 8–16 hr
after IR. Furthermore, this slow DNA repair is DNA-PK indepen-
dent given that it could not be inhibited by NU7441. HSCs, which
cannot use HR because of their quiescent status, are more
vulnerable than progenitors to the acquisition of IR-induced
genome rearrangements (Mohrin et al., 2010). However, our
data suggest that environmental BM signals can act to limit
this phenomenon by increasing the global efficiency of NHEJ-
mediated repair through its fast DNA-PK-dependent compo-
nent. Interestingly, expression of the main DNA-PK-dependent
classic NHEJ proteins Ku80 and DNA-Ligase IV has been shown
to be downregulated by Flt3-ITD and Bcr-Abl oncogenes
(Fan et al., 2010). Recent data have shown that leukemic stem
cells can arise not only from HSCs but also from committed
primitive progenitors (Passegue´ and Weisman, 2005). TPO was
found to regulate DNA-PK-dependent DSB repair in both
myeloid progenitors and HSC-enriched cells, and this pathway
is downregulated in Mpl+/ and Mpl/ cells. This suggests
that the loss or reduced expression of Mpl could lead to hema-
topoietic malignancies and a tumor-suppressor role for this
receptor in response to IR. This possibility is in agreement with
the increased propensity of CAMT patients to develop AML
(Maserati et al., 2008). Interestingly, increased sensitivity to
preconditioning treatments and the presence of chromosomal
aberrations resembling that found in therapy-induced MDS
and AML have been described for those patients (Maserati
et al., 2008; Steele et al., 2005). We could not observe malignan-
cies inMpl/ mice sacrificed 5 months after TBI. This might be
due to the long latency for IR-induced leukemia development in
mice and the resistance to C57Bl/6 strain to AML and MDS.
Thus, additional studies are required for validation of this
hypothesis.
FullMpl expression is required for TPO-mediated DNA repair.
This requirement for high TPO signaling may explain why an
acute injection of TPO to TPO-proficient mice can increase
DNA repair. However, the loss of DSB repair function of Mpl+/
cells is intriguing given that these mice, in contrast with Mpl/
mice (Kimura et al., 1998; Qian et al., 2007), have normalCell Stem Cell 12, 37–48, January 3, 2013 ª2013 Elsevier Inc. 45
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and also have reconstitution ability (B.d.L., L.P.-C., M.S., and F.
Porteu, unpublished data). Thus, Mpl is haplosufficient for
HSC maintenance and expansion posttransplantation but not
for DNA damage response to IR, suggesting that these functions
are separately controlled. In agreement with this possibility, the
critical role of TPO in adult HSC maintenance has been shown
to primarily reflect its ability to regulate HSC quiescence (Qian
et al., 2007; Yoshihara et al., 2007), whereas the TPO-induced
DNA repair reported here and HSC radiosensitivity (Mohrin
et al., 2010) are independent of their quiescence.
Mice or humans exposed to moderate or high doses of IR
exhibit residual defects in HSC function even after hematopoi-
esis has recovered months after exposure (Marusyk et al.,
2009; Simonnet et al., 2009; Wang et al., 2006). In addition, IR
increases the probability of the occurrence of oncogenic muta-
tions. A recent report has demonstrated that HSPCs forced to
proliferate before IR exposure through the application of an
in vivo mobilization treatment to mice with granulocyte colony-
stimulating factor (G-CSF) and cyclosphosphamide have sig-
nificantly decreased mutation rates because of enhanced
DNA-repair fidelity in conjunction with the preservation of their
relative radioresistance in vitro (Mohrin et al., 2010). However,
G-CSF injection has also been shown to promote HSPC pro-
liferation and differentiation at the expense of HSC self-renewal
(van Os et al., 2000), inducing a differentiation checkpoint in the
context of DNA damage (Wang et al., 2012). Abrogation of this
checkpoint prolongs HSC self-renewal but results in DNA-
damage accumulation. Thus, the routine use of G-CSF to hasten
recovery from radiotherapy or chemotherapy-induced neutrope-
nia may decrease HSCs’ mutagenesis but impair their function.
Our results show that short-term specific exposure to TPO
in vitro or in vivo protects HSCs from IR-induced genomic insta-
bility and rescues, at least partially, their loss of activity. TPO also
increases the repair of DSBs induced by etoposide and DXR.
Romiplostim was found to recapitulate TPO effects on both
short-term and long-term TBI-induced accumulation of DNA
damage in HSCs. Thus, our results may have important clinical
implications in opening new avenues for the use of TPO agonists
prior to therapy with DNA-damaging agents to minimize the risk
of secondary AML and long-term residual HSPC injury. Impor-
tantly, although we have not tried to optimize the dose of TPO
used, a single injection just before exposure to IR proved
sufficient to induce some long-term protection against DNA
damage. This may avoid the described adverse complications
induced by prolonged, but not by acute, treatments with TPO
or its agonists (Ikeda and Miyakawa, 2009; Le´on et al., 2012).EXPERIMENTAL PROCEDURES
Mice, Cell Culture, and Reconstitution Assays
Mpl/ backcrossed on C57BL/6 (CD45.2) background (kindly provided by
Dr F. de Sauvage) and 129S2/Sv KitW-v/KitW-vmice were described previously
(Petit-Cocault et al., 2007; Allix et al., 2008). C57BL/6J (CD45.2 and CD45.1)
and CB17-Prkdc-scid mice were purchased from Charles River and Harlan
laboratories, respectively. Unless otherwise specified, mice of 8–10 weeks
of age were used. All procedures were approved by the Animal Care
Committee (registered no. P2.MG.137.10, 2010) and the department director
of veterinary services of Paris (agreement no. 75-1064). Lin, LSK, and LSK-
CD34 cells were isolated from BM and stained as described (Saulnier46 Cell Stem Cell 12, 37–48, January 3, 2013 ª2013 Elsevier Inc.et al., 2012). The cells were cultured in StemSpan serum-free expansion
medium (SFEM, STEMCELL Technologies) supplemented with recombinant
Flt3 ligand (100 ng/ml), interleukin-3 (IL-3, 10 ng/ml), IL-6 (10 ng/ml), SCF
(100 ng/ml), and TPO (50 ng/ml), all from PeproTech (Rocky Hill, NJ, USA),
(complete medium) or in the same medium without TPO. CD34+ and CD34+
CD38 human HSPCs were isolated from cord blood or cytapheresis, as
described (Hamelin et al., 2006). UT7-Mpl cells were cultured in a-MEM
supplemented with 10% fetal calf serum (FCS) and 2 U/ml EPO (Boehringer
Ingelheim). Cell IR in vitro was carried out in a BIOBEAM 8000 irradiator
(Gamma-Service Medical GmbH, Leipzig, Germany). Mouse TBI was per-
formed in an IBL 637 cesium irradiator (Curie Institute, Paris). For competitive
reconstitution experiments, 3,000 LSK cells sorted from C57BL/6 CD45.1
mice subjected to TBI (2 Gy) or not as well as TPO injection (8 mg/kg body
weight) were injected in lethally irradiated (10 Gy) C57BL/6 CD45.2 congenic
mice, together with 3 3 105 BM CD45.2 competitor cells, and analyzed
4 months later.
Immunofluorescence
Immunofluorescence was performed as described (Pawlikowska et al., 2010),
with cells cytospun on glass slides. Slides were visualized with a Leica DMI
6000 microscope (Wetzlar, Germany) equipped with a 63 3 1.6 oil-immersion
objective and a Micromax charge-coupled device camera (Princeton Instru-
ments, Trenton, NJ, USA). Pictures were analyzed using ImageJ software.
Comet and Cytogenetic Assays
The neutral comet assay and chromosomal-aberration analysis in metaphase
spreads were performed as described (Pawlikowska et al., 2010). Three-color
FISH was performed using whole-chromosome probes for mouse chromo-
somes 2 (fluorescein isothiocyanate [FITC]), 6 (Texas red), and 12 (FITC:Texas
red) (MetaSystems, Altlussheim, Germany), and counterstaining was per-
formed with DAPI-Antifade solution (Qbiogene, Illkirch, France), as reported
(Pouzoulet et al., 2007). Fluorescence was analyzed with a Zeiss Axioplan
epifluorescent microscope and Isis-multicolor FISH (mFISH) imaging system
(MetaSystems).
Cell-Cycle Analysis
Cell cycle was analyzed by staining Lin cells with Hoechst and Pyronin Y and
with anti-CD34, Sca1, and c-Kit (Saulnier et al., 2012). Analysis was performed
using an LSRII flow cytometer (BD Biosciences) and FlowJo software
(TreeStar).
NHEJ Assays
UT7-Mpl cells were electroporated with the NHEJ pCOH substrate (Guirouilh-
Barbat et al., 2004), and clonal populations were selected in the presence of
blasticidin (40 mg/ml). Expression of the meganuclease I-SceI was achieved
by electroporation of pcDNA-HA-I-SceI, using Amaxa Kit V (Lonza, Amaxa,
Basel). The cells were then cultured in medium containing 2 U/ml EPO or
3 nM TPO peptide (Hamelin et al., 2006). End-joining was analyzed 48 hr to
1 week later. For assessing I-SceI expression, the cells were permeabilized
by treatment with 0.1% Triton X-100 (10 min, room temperature [RT]) and
methanol (50%, 10 min, 4C) and stained with anti-hemagglutinin (HA) fol-
lowed by anti-mouse-FITC antibodies.
For testing NHEJ activity on primary cells, WT and Mpl/ LinKit+ cells
were cultured in StemSpan SFEM containing 25 ng/ml SCF, 25 ng/ml IL-11,
10 ng/ml IL-3, 50 ng/ml TPO, and 10 ng/ml granulocyte-macrophage
colony-stimulating factor (GM-CSF). After 24 hr, cells were irradiated and
electroporated with 1.5 mg of HindIII-digested pEGFP-Pem1-Ad2 plasmid
(Seluanov et al., 2004) and 0.5 mg of pDsRed-Express (Clontech Laboratories,
Mountain View, CA, USA) using Amaxa Kit V. Cells were analyzed by flow cy-
tometry 24 hr later.
Statistical Analysis
Results were evaluated using either one-way ANOVA and Tukey comparison
test or unpaired t test by GraphPad Prism version 5.0 software (GraphPad
Software, San Diego, CA, USA). For FISH analysis, a specific chi-square test
adapted to Poisson statistics was used (Pouzoulet et al., 2007). Results are
shown as means and SEM and the value of *p < 0.05 was determined as sig-
nificant, and **p < 0.01 or ***p < 0.001 as highly significant.
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